{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 89 of 129', 'Treatment difference in response rates of IGA 0/1 and EASI75 after 16 weeks', 'if all subjects adhered to the treatment regimen in the sense that they did not', 'discontinue IMP permanently and no rescue medication was made available', 'before Week 16.', 'The secondary estimand assesses the expected difference in response rates achieved when', 'adhering to the treatment regimen tralokinumab+TCS with no rescue medication as compared', 'to a treatment regimen with placebo+TCS with no rescue medication.', 'Primary analysis of the secondary estimand', 'Data collected after permanent discontinuation of IMP or after initiation of rescue medication', 'will not be applied in the analysis.', 'IGA 0/1 responder imputation', 'Imputation of missing binary IGA 0/1 data at Week 16 will be done using multiple', 'imputations of the underlying 5-point IGA values within the 2 groups defined according to', 'randomised treatment arm assuming that data is missing at random within each arm.', '1. In each group, intermittent missing values will be imputed using LOCF to obtain a', 'monotone missing data pattern.', '2. An ordinal logistic regression model assuming proportional odds will be fitted to the', 'IGA value at Week 2. The model will include effects of region, and baseline disease', 'severity (IGA 3 or 4) as factors. The estimated parameters, and their variances, will be', 'used to impute missing IGA values at Week 2. 100 copies of the dataset will be', 'generated (seed=111099).', '3. For each of the 100 copies of the dataset, missing values at Week 4 will be imputed in', 'the same way as for Week 2. The imputations will be based on a proportional odds', 'logistic regression model with effects of region and baseline disease severity (IGA 3 or', '4) together with the IGA value at Week 2 as factors. The estimated parameters, and', 'their variances, will be used to impute missing values at Week 4.', '4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14,', 'and 16 with the modification that only the IGA values from the two preceding visits', 'will be included as factors in addition to region and baseline disease severity. The', 'missing binary IGA 0/1 response at Week 16 will be derived from the corresponding', 'underlying imputed IGA value.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 90 of 129', 'EASI75 responder imputation', 'Imputation of missing binary EASI75 data at Week 16 will be done using multiple', 'imputations of the underlying 72-point EASI values within the two groups defined according', 'to randomised treatment arm assuming that data is missing at random within each arm.', '1. Intermittent missing values will be imputed in each group using a Markov Chain', 'Monte Carlo method to obtain a monotone missing data pattern and 100 copies of the', 'dataset will be generated (seed=290997).', '2.', 'An ANCOVA model is fitted to the EASI value at Week 2. The model will include', 'effects of baseline EASI as a covariate, and region, and baseline disease severity (IGA', '3 or 4) as factors. The estimated parameters, and their variances, will be used to', 'impute missing EASI values at Week 2. 100 copies of the dataset will be generated', '(seed=111099).', '3. For each of the 100 copies of the dataset, missing EASI values at Week 4 will be', 'imputed in the same way as for Week 2. The imputations will be based on the same', 'ANCOVA model with effects of baseline EASI as a covariate, and region, and baseline', 'disease severity (IGA 3 or 4) as factors together with the EASI value at Week 2 as', 'covariate. The estimated parameters, and their variances, will be used to impute', 'missing values at Week 4.', '4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14,', 'and 16 with the modification that only the EASI values from the preceding two visits', 'will be included as covariates in addition to baseline EASI as a covariate, and region', 'and baseline disease severity as factors. The missing binary EASI75 response at', 'Week 16 will be derived from the corresponding underlying imputed EASI value.', 'Analysis of Week 16 response', 'For each of the 100 complete data sets, the difference in response rates (either the IGA 0/1 or', 'the EASI75) between treatment groups will be analysed using the Cochran-Mantel-Haenszel', 'test stratified by region (Europe and North America) and baseline disease severity (IGA 3 or', '4). The estimates and standard errors from the 100 analyses will be pooled to one estimated', \"treatment difference and associated standard error using Rubin's rule to draw inference. From\", 'these pooled estimates, the 95% CI for the treatment difference will be calculated.', 'Sensitivity analysis for the secondary estimand', 'Rather than assuming that observations are missing at random within each treatment arm, it is', 'assumed that missing data from subjects who discontinue IMP permanently/receive rescue', 'medication in the tralokinumab+TCS arm will resemble missing data from subjects from the', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}